Pathogenic monoclonal antibody against desmoglein 3 augments desmoglein 3 and p38 MAPK phosphorylation in human squamous carcinoma cell line.
about
The desmosomep38MAPK signaling and desmoglein-3 internalization are linked events in pemphigus acantholysis.Desmoglein 3, via an interaction with E-cadherin, is associated with activation of SrcDSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathwayPemphigus in the XXI century: new life to an old story.The desmosome and pemphigus.A pathophysiologic role for epidermal growth factor receptor in pemphigus acantholysisAutoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skinApoptotic pathways in pemphigus.Pemphigus autoimmunity: hypotheses and realities.Diagnosis and treatment of pemphigus.p38 MAPK Signaling in Pemphigus: Implications for Skin AutoimmunityDesmosomes and extradesmosomal adhesive signaling contacts in pemphigus.Desmoglein 3: a help or a hindrance in cancer progression?MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris.Non-junctional human desmoglein 3 acts as an upstream regulator of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis of pemphigus vulgaris.Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in pemphigus acantholysis.Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus.Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens.Differential coupling of M1 muscarinic and alpha7 nicotinic receptors to inhibition of pemphigus acantholysis.Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.Autoantibody Signaling in Pemphigus Vulgaris: Development of an Integrated Model.
P2860
Q24656653-DB2E3D6F-B4B5-4D22-A48C-C2963EC3F236Q33726526-AC16836C-89AB-40F4-ACEC-976F2AE0D3AAQ33769643-BC250B02-FF3D-4445-B8EA-C0880FFBBD7FQ34758600-E15C5A3E-642E-4388-AC18-AD2219FC493CQ36668531-4B87AFC8-7E55-4DF2-8A3E-9C379CCC41DEQ36700065-58F356AD-9C07-4954-A65F-0AAE17A99AE5Q36725116-161DD958-10E7-4C02-9359-DBB1B039BD00Q37061072-FEFF04D4-6711-4C0B-B697-EB0FE384F9FBQ37772779-0C84C687-8CA8-4499-B4B0-7BEF08E03CD4Q37937040-0E65DB70-03FE-439F-947B-0A13438733DDQ38031283-E5A5BD40-E838-46A7-8F51-6BA26E1A5A2AQ38128304-3CAE1DDE-E31C-446D-802E-374843C1FD7EQ38189277-D24C6A74-CF37-4FE0-A1D3-FF5441311329Q38335478-8AE24FAC-C9B3-432C-AD1B-5440BE7D8325Q39154700-74055D3A-29A8-42F0-98AF-935E2FEE8DE7Q39403372-A1F131E6-885F-4F30-A483-374E106DFE18Q41969896-2FB826A0-7919-4CA9-A94B-2BEE0FBE8E19Q42151518-39F5B914-EC9B-4036-A849-ED182F4C40FDQ43513002-983D6A34-EBCA-4756-8BDC-EDEB9308164DQ46003595-6C51364E-32D4-427E-9829-A0ED896A9E72Q47219879-9894E6BE-167F-4069-AE36-28FCA023EDFDQ55110690-DC66C740-E25A-485D-A82F-17AD0BCF6361
P2860
Pathogenic monoclonal antibody against desmoglein 3 augments desmoglein 3 and p38 MAPK phosphorylation in human squamous carcinoma cell line.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pathogenic monoclonal antibody ...... squamous carcinoma cell line.
@en
type
label
Pathogenic monoclonal antibody ...... squamous carcinoma cell line.
@en
prefLabel
Pathogenic monoclonal antibody ...... squamous carcinoma cell line.
@en
P2093
P2860
P1433
P1476
Pathogenic monoclonal antibody ...... squamous carcinoma cell line.
@en
P2093
Kazuyuki Tsunoda
Yasuo Kitajima
Yuki Kawasaki
Yumi Aoyama
P2860
P304
P356
10.1080/08916930600971943
P577
2006-11-01T00:00:00Z